{
  "slug": "granza-bio",
  "name": "Granza Bio",
  "yc_id": 29485,
  "batch": "Winter 2024",
  "website": "https://www.granzabio.com/",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:30:05.539516",
    "website": "https://www.granzabio.com/",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 1561.22,
      "final_url": "https://www.granzabio.com/",
      "redirected": false,
      "checked_at": "2025-10-17T01:30:07.100755"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "granzabio.com",
      "registrar": "GoDaddy.com, LLC",
      "creation_date": "2023-12-20T18:56:32",
      "expiration_date": "2029-12-20T18:56:32",
      "domain_age_days": 666,
      "domain_age_years": 1.8,
      "name_servers": [
        "NS07.DOMAINCONTROL.COM",
        "NS08.DOMAINCONTROL.COM"
      ]
    },
    "social_links": {
      "twitter": null,
      "linkedin": null,
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": true,
      "content_security_policy": true,
      "x_frame_options": true,
      "x_content_type_options": false,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 50,
      "server": "cloudflare"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:39:20.584236",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0",
    "model_used": "claude-sonnet-4-20250514",
    "enriched_at": "2025-10-17T11:44:44.886717",
    "status": "success",
    "market_analysis": {
      "market_size": "very large",
      "market_stage": "growing",
      "key_trends": [
        "Shift from systemic to targeted drug delivery",
        "Growing demand for RNA therapeutics delivery solutions",
        "Increasing focus on reducing off-target effects and toxicity"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Proprietary non-immunogenic protein-based delivery platform with tissue-specific targeting capabilities",
      "differentiation": "Non-immunogenic protein shells with targeting receptors vs conventional lipid nanoparticles",
      "competitive_advantages": [
        "Higher stability than LNPs",
        "Versatile cargo compatibility (proteins, DNA, RNA)",
        "Reduced immunogenicity profile"
      ],
      "competitive_vulnerabilities": [
        "Early-stage technology requiring extensive validation",
        "Competing against established LNP platforms with proven track records"
      ]
    },
    "business_model": {
      "revenue_model": "Biotech licensing/partnerships",
      "scalability": "high",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "seed",
      "growth_indicators": [
        "Y Combinator backing",
        "Novel platform technology",
        "Large addressable market"
      ],
      "growth_bottlenecks": [
        "Lengthy preclinical and clinical development timelines",
        "Need for significant capital for R&D and trials"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "high",
      "overall_risk_score": 8,
      "key_risks": [
        "Unproven platform technology",
        "Regulatory approval uncertainty",
        "Competition from established delivery platforms"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Addresses critical need in targeted drug delivery",
        "Potential to improve therapeutic index",
        "Versatile platform applicable to multiple therapeutic modalities"
      ],
      "concerns": [
        "Early-stage technology with limited validation",
        "High capital requirements and long development timelines"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Moderna",
        "Alnylam Pharmaceuticals"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Demonstrate proof-of-concept in lead indication",
        "Secure strategic partnerships with pharma companies"
      ],
      "expansion_opportunities": [
        "Platform licensing to multiple therapeutic areas",
        "Development of proprietary therapeutic programs"
      ]
    },
    "tokens_used": {
      "input": 730,
      "output": 587,
      "total": 1317,
      "estimated_cost": 0.010995
    }
  },
  "phase8_complete": true
}